Seeking Alpha
 

Inovio Pharmaceuticals, Inc. (INO)

- NASDAQ
  • Mon, Aug. 10, 7:30 AM
    • Inovio Pharmaceuticals (INO -4.6%) Q2 results: Revenues: $5.3M (+39.5%); R&D Expense: $16.7M (+74.0%); SG&A: $4.7M (+9.3%); Operating Loss: ($15.1M) (-48.0%); Net Loss: ($6.2M) (+42.1%); Loss Per Share: ($0.09) (+52.6%); Quick Assets: $154.6M (+65.2%).
    • No guidance given.
    | Mon, Aug. 10, 7:30 AM | 2 Comments
  • Mon, Aug. 10, 6:12 AM
    • Inovio Pharmaceuticals (NASDAQ:INO): Q2 EPS of -$0.09 beats by $0.04.
    • Revenue of $5.3M (+39.5% Y/Y) misses by $0.22M.
    • Shares +9.4% PM.
    • Press Release
    | Mon, Aug. 10, 6:12 AM | 1 Comment
  • Mon, May 11, 9:09 AM
    • Inovio Pharmaceuticals (INO -0.9%) Q1 results: Revenues: $5.2M (+116.7%); R&D Expense: $9.4M (+14.6%); SG&A: $4.1M (-0.7%); Operating Loss: ($8.4M) (+16.0%); Net Loss: ($10.6M) (+1.9%); Loss Per Share: ($0.18) (+10.0%); Quick Assets: $81M (-13.5%).
    • No guidance given.
    | Mon, May 11, 9:09 AM | Comment!
  • Mon, May 11, 7:02 AM
    • Inovio Pharmaceuticals (NASDAQ:INO): Q1 EPS of -$0.18 misses by $0.07.
    • Revenue of $5.17M (+119.1% Y/Y) misses by $1.87M.
    • Press Release
    | Mon, May 11, 7:02 AM | Comment!
  • Mon, Mar. 16, 7:50 AM
    • Inovio Pharmaceuticals (INO -3.6%) Q4 results: Revenues: $2.5M (+47.1%); R&D Expense: $9.2M (+43.8%); SG&A: $4.2M (-2.3%); Net Loss: ($7.4M) (+52.3%); Loss Per Share: ($0.12) (+60.0%).
    • FY2014 results: Revenues: $10.5M (-22.2%); R&D Expense: $34.1M (+59.3%); SG&A: $15.9M (+16.9%); Operating Loss: ($39.5M) (-102.6%); Net Loss: ($36.1M) (+45.3%); Loss Per Share: ($0.64) (+55.2%); Quick Assets: $93.6M (+77.9%).
    • No guidance given.
    | Mon, Mar. 16, 7:50 AM | 1 Comment
  • Mon, Mar. 16, 6:43 AM
    • Inovio Pharmaceuticals (NASDAQ:INO): Q4 EPS of -$0.12 misses by $0.02.
    • Revenue of $2.5M (+43.7% Y/Y) misses by $2.74M.
    • Press Release
    | Mon, Mar. 16, 6:43 AM | Comment!
  • Nov. 10, 2014, 11:06 AM
    • Inovio Pharmaceuticals (INO -4.3%) Q3 results: Revenues: $1.8M (-81.1%); R&D Expense: $7M (+29.6%); G&A: $3.2M (-3.0%); Operating Loss: ($8.3M) (-999%); Net Loss: ($7.2M) (+76.7%); Loss Per Share: ($0.12) (+81.3%); Quick Assets: $100.9M (+91.5%).
    • No guidance given.
    | Nov. 10, 2014, 11:06 AM | Comment!
  • Nov. 10, 2014, 6:59 AM
    • Inovio Pharmaceuticals (NASDAQ:INO): Q3 EPS of -$0.12 beats by $0.02.
    • Revenue of $1.8M (-81.0% Y/Y) misses by $3.78M.
    • Press Release
    | Nov. 10, 2014, 6:59 AM | Comment!
  • Nov. 4, 2014, 11:57 AM
    • Inovio Pharmaceuticals (INO -2.1%) will report Q3 results on November 10 before the open. The conference call will begin at 8:00 am ET.
    • Consensus view is a loss of ($0.14) on revenues of $5.6M.
    | Nov. 4, 2014, 11:57 AM | Comment!
  • Aug. 11, 2014, 11:18 AM
    • Inovio Pharmaceuticals (INO -6.9%) Q2 results: Revenues: $3.8M (+383.9%); Operating Expenses: $14.0M (+116.1%); Operating Loss: ($10.2M) (-79.0%); Net Loss: ($10.7M) (+1.4%); Loss Per Share: ($0.19) (+8.3%); Quick Assets: $108.8M (+106.8%).
    • No financial guidance given.
    | Aug. 11, 2014, 11:18 AM | 1 Comment
  • Aug. 11, 2014, 8:36 AM
    • Inovio Pharmaceuticals (NYSEMKT:INO): Q2 EPS of -$0.19 in-line.
    • Revenue of $3.8M (+387.2% Y/Y) beats by $2M.
    • Press Release
    | Aug. 11, 2014, 8:36 AM | Comment!
  • May 12, 2014, 9:02 AM
    • Inovio (INO) revenues: $1.4M vs $14.3K; net loss: ($108M) (-21.3%); loss/share: ($0.05) (+16.7%); quick assets (ex-A/R): $116.8M (+122.1%).
    • Capital position should be sufficient to fund the firm's operations through 2017.
    • Management expects to report data on the Phase 2 trial for VGX-3100, SynCon immunotherapy against HPV-caused cancers and pre-cancers delivered with the Cellectra electroporation device by mid-year.
    • INO-5150 cancer immunotherapy Phase 1 trial to be launched in Q3. This will trigger a milestone payment from partner Roche (RHHBY). 
       
    | May 12, 2014, 9:02 AM | 4 Comments
  • May 12, 2014, 6:57 AM
    • Inovio Pharmaceuticals (INO): Q1 EPS of -$0.05 misses by $0.01.
    • Revenue of $2.4M (+62% Y/Y) beats by $0.99M.
    • Press Release
    | May 12, 2014, 6:57 AM | 7 Comments
  • Mar. 17, 2014, 6:18 AM
    • Inovio Pharmaceuticals (INO): Q4 EPS of -$0.07 misses by $0.04.
    • Revenue of $1.7M beats by $0.34M.
    • Press Release
    | Mar. 17, 2014, 6:18 AM | 2 Comments
  • Nov. 13, 2013, 12:58 PM
    • Inovio Pharmaceuticals (INO +4.6%) trades higher on the heels of the company's Q3 report.
    • INO said it had cash and equivalents of $46.3M as of September 30 and received some $11M more thereafter, most of which is attributable to a $10M upfront payment from Roche. For more on the Roche deal, see here.
    • Commenting, analyst Raghuram Selvaraju says that although Aegis "expects positive data from INO's cervical cancer vaccine Phase 2 study in the coming months, INO shares currently represent a relatively neutral risk/reward proposition."
    • Hold rating maintained.
    • Price target is $2.50.
    | Nov. 13, 2013, 12:58 PM | Comment!
  • Nov. 12, 2013, 6:36 AM
    • Inovio Pharmaceuticals (INO): Q3 EPS of -$0.16.
    • Revenue of $9.5M beats by $6.61M. (PR)
    | Nov. 12, 2013, 6:36 AM | 5 Comments
Visit Seeking Alpha's
INO vs. ETF Alternatives
Company Description
Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.
Sector: Healthcare
Industry: Biotechnology
Country: United States